Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2022 | PTCy in unrelated and haploidentical donor alloHSCT in CML

Guillermo Ortí • 21 Mar 2022
EBMT 2022
Chronic Myeloid Leukemia Leukemia Cyclophosphamide

Guillermo Ortí, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, outlines the rationale and design of a retrospective study exploring the outcomes of patients with chronic myeloid leukemia (CML) undergoing unrelated and haploidentical donor allogeneic hematopoietic stem cell transplantation (alloHSCT) with post-transplant cyclophosphamide (PTCy) prophylaxis compared to a historical cohort of patients who have received unrelated donor alloHSCT with calcineurin inhibitor prophylaxis. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.

More from Guillermo Ortí

1:39
Emerging therapeutic approaches for TKI-resistant CML
Guillermo Ortí • 21 Mar 2022
1:08
Latest advances in BP-MPNs
Guillermo Ortí • 21 Mar 2022
1:23
Current status of alloHSCT in BP-MPNs
Guillermo Ortí • 21 Mar 2022
1:47
State of the art in CML
Guillermo Ortí • 21 Mar 2022

Related Videos

1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals